BusinessFoundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2ABy Nasdaq OMXFeb 12, 2018, 12:01 PM UTC
BusinessProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMABy Nasdaq OMXSep 5, 2017, 11:01 AM UTC
BusinessProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher SyndromeBy Nasdaq OMXMay 1, 2017, 11:01 AM UTC
